ScienceDaily: Most Popular News |
| Rilzabrutinib for blood disorder shows promise in phase 1--2 clinical trial Posted: 15 Apr 2022 07:05 AM PDT In an international phase 1--2 clinical trial of patients with immune thrombocytopenia, an oral investigational drug called rilzabrutinib was active and associated with only low-level toxic effects at all dose levels. |
| You are subscribed to email updates from Latest Science News -- ScienceDaily. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |